Abstract:7 Supplementary Tables: Supplementary Table S1. Association between LIMS1 expression and clinicopathological features of patients with PDAC. Supplementary Table S2. Association between LIMS1 mRNA expression and clinicopathological features of PDAC patients from TCGA. Supplementary Table S3. Cox's proportional hazards model analysis of prognostic factors in patients with pancreatic ductal adenocarcinoma (PDAC) Supplementary Table S4. Association between LIMS1 expression and clinicopathological features of patients with esophageal cancer. Supplementary Table S5. Association between LIMS1 expression and clinicopathological features of patients with lung adenocarcinoma. Supplementary Table S6. Main antibodies and reagents. Supplementary Table S7. Primers and oligonucleotides sequences.

Supplementary Table 3 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Figure S2 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Figure S1 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Figure S4 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Table S1, S2, S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Supplemental Table S1 from RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells

Supplementary Materials and Methods from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Supplementary Tables 1-3 from Activation of the Signal Transducers and Activators of the Transcription 3 Pathway in Alveolar Epithelial Cells Induces Inflammation and Adenocarcinomas in Mouse Lung

Supplementary Table 3 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Table S14 from Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Supplementary Table S4 from Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival

Supplementary Table 2 from Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer

Supplementary Table 4 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression

Supplementary Table from Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability

Supplementary Table 2 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression